PT-141 is a synthetic peptide hormone developed by Palatin Technologies and approved by the FDA in 2019 for treating hypoactive sexual desire disorder (HSDD). It is the first FDA-approved treatment for HSDD in premenopausal women.
PT-141 works by activating the melanocortin receptors in the brain, which are involved in sexual arousal and desire. When administered, PT-141 travels through the bloodstream to the brain where it binds to and activates these receptors, leading to increased sexual arousal and desire within 30-60 minutes.
Some key benefits of PT-141 include:
PT-141 has been shown in clinical trials to significantly increase sexual desire, arousal, pleasure, and satisfaction in premenopausal women with HSDD. In one pivotal trial, 86% of women reported improvements in sexual desire, and 67% reported statistically significant improvements in sexual activity after taking PT-141.
Compared to other treatments for HSDD like Viagra or testosterone, PT-141 works more selectively on brain pathways involved in sexual desire and arousal. As a result, side effects are minimal - mainly mild nausea, flushing, and headaches that resolve quickly. It does not increase erections in men or masculinize women.
How is PT-141 administered?
PT-141 comes as a nasal spray that is administered about 45 minutes before anticipated sexual activity. The recommended dose is 1.8 mg per spray in each nostril. Most people notice effects within 30-60 minutes that can last up to 6 hours.
At Renew Clinic, we provide PT-141 nasal spray and injections, along with comprehensive hormone testing and treatment plans for hypogonadism, menopause, and other hormonal conditions. Our caring medical team has over 10 years of experience optimizing hormones for health, vitality, and an improved quality of life.
Interested in learning more about PT-141 and other cutting-edge hormone therapies? Schedule a consultation at Renew Clinic today! We look forward to helping you restore your hormones and reclaim your health.